Quantification of plasma and intracellular levels of the HIV protease inhibitor ritonavir by competitive ELISA
- 21 February 2002
- journal article
- Published by Elsevier in Journal of Immunological Methods
- Vol. 263 (1-2) , 1-9
- https://doi.org/10.1016/s0022-1759(02)00026-1
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Therapeutic Drug Monitoring of HIV Protease Inhibitors Using High-Performance Liquid Chromatography With Ultraviolet or Photodiode Array DetectionTherapeutic Drug Monitoring, 2001
- The role of therapeutic drug monitoring in treatment of HIV infectionBritish Journal of Clinical Pharmacology, 2001
- Efficacy and safety of twice daily first-line ritonavir/indinavir plus double nucleoside combination therapy in HIV-infected individualsAIDS, 2000
- Antiretroviral Therapy in AdultsJAMA, 2000
- Simultaneous determination of the HIV-protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 1999
- Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral TherapyNew England Journal of Medicine, 1997
- ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans.Proceedings of the National Academy of Sciences, 1995
- Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase.Proceedings of the National Academy of Sciences, 1986
- Molecular Forms of Electrophorus AcetylcholinesteraseEuropean Journal of Biochemistry, 1976
- A new and rapid colorimetric determination of acetylcholinesterase activityBiochemical Pharmacology, 1961